


Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

November 2026

The logo for PHARMAC (Te Pātaka Whaioranga) is centered within a white circle. The background of the entire page is a solid grey color. Below the circle, there are stylized, concentric, wavy lines in white and grey, resembling a stylized 'S' or a series of overlapping waves. The text 'PHARMAC' is in a large, bold, sans-serif font, and 'TE PĀTAKA WHAIORANGA' is in a smaller, all-caps, sans-serif font below it.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 November 2026..... 3

Changes to General Rules..... 6

Section H changes to Part II 7

Index 18

Summary of decisions

EFFECTIVE 1 NOVEMBER 2026

- Abacavir sulphate tab 300 mg (Ziagen) and oral liq 20 mg per ml – removal of restriction criteria
- Abacavir sulphate with lamivudine (Abacavir/lamivudine Viatris) tab 600 mg with lamivudine 300 mg – removal of restriction criteria
- Adalimumab (Amgevita) inj 20 mg per 0.4 ml prefilled syringe, inj 40 mg per 0.8 ml prefilled pen and inj 40 mg per 0.8 ml prefilled syringe – amended restriction criteria
- Adalimumab (Humira - Alternative Brand) inj 20 mg per 0.2 ml prefilled syringe and inj 40 mg per 0.4 ml prefilled syringe (Humira) and inj 40 mg per 0.4 ml prefilled pen (HumiraPen) – amended restriction criteria
- Antiretrovirals – addition of note
- Aspirin (Ethics Aspirin) tab dispersible 300 mg – price increase and addition of PSS
- Atazanavir sulphate (Atazanavir Viatris) cap 150 mg and cap 200 mg – removal of restriction criteria
- Bedaquiline (Sirturo) tab 100 mg – amended restriction criteria
- Calcitriol (Calcitriol Devatis) cap 0.25 mcg and cap 0.5 mcg – PSS start date delayed
- Calcitriol (Calcitriol XL and Calcitriol-AFT) cap 0.25 mcg and cap 0.5 mcg – delisting delayed
- Captopril (DP-Captopril) oral liq 5 mg per ml, 100 ml – amended restriction criteria
- Ceftolozane with tazobactam (Zerbaxa) inj 1,000 mg with tazobactam 500 mg, 20 ml vial – new listing and addition of restriction criteria
- Cetirizine hydrochloride (Noumed Cetirizine Hayfever & Allergy Relief) oral liq 1 mg per ml – new listing and addition of PSS
- Cetirizine hydrochloride (Histaclear) oral liq 1 mg per ml – to be delisted 1 April 2027
- Citric acid with magnesium oxide and sodium picosulfate (e.g. Picosalax) powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet – new listing
- Darunavir (Darunavir Viatris) tab 400 mg and tab 600 mg – removal of restriction criteria
- Dolutegravir tab dispersible 5 mg – new listing
- Dolutegravir tab 50 mg (Tivicay) and tab dispersible 5 mg – removal of restriction criteria
- Dolutegravir with lamivudine (Dovato) tab 50 mg with lamivudine 300 mg – removal of restriction criteria
- Efavirenz tab 600 mg (Efavirenz Milpharm) and oral liq 30 mg per ml – removal of restriction criteria
- Efavirenz with emtricitabine and tenofovir disoproxil tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate) (Viatris) and tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate) (TEEVR, TEEVR (India), Tenofovir Efavirenz Emtricitabine(Mylan)) – removal of restriction criteria

Summary of decisions – effective 1 November 2026 (continued)

- Emtricitabine (Emtriva) cap 200 mg – removal of restriction criteria
- Emtricitabine with tenofovir disoproxil tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) (Tenofovir Disoproxil Emtricitabine Viatr) and tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate) (Tenofovir Disoproxil Emtricitabine Mylan) – removal of restriction criteria
- Etravirine (Intelence) tab 200 mg – removal of restriction criteria
- Flecainide acetate (Almarytm and Tambocor German) inj 10 mg per ml, 15 ml ampoule – delisted 1 November 2026
- Fluconazole (APO Fluconazole) cap 200 mg – new listing
- Human papillomavirus (6, 11, 16, 18, 31, 33, 45, 52 and 58) vaccine [HPV] (Gardasil 9) inj 270 mcg in 0.5 ml syringe – amended restriction criteria
- Hydrocortisone acetate (Cortifoam) rectal foam 10%, CFC free (14 applications) – new listing
- Ibrutinib (Imbruvica) tab 140 mg and tab 420 mg – amended restriction criteria
- Ibuprofen (Ibuprofen-AFT) tab 200 mg - 20 tablet pack – new listing and addition of PSS
- Imatinib mesylate (Imatinib-Rex) cap 100 mg and cap 400 mg – price decrease and addition of PSS
- Indinavir cap 200 mg and cap 400 mg – removal of restriction criteria
- Insulin aspart with insulin aspart protamine (NovoMix 30 FlexPen) inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen – to be delisted 1 July 2027
- Ipilimumab (Yervoy) inj 5 mg per ml, 10 ml vial and inj 5 mg per ml, 40 ml vial – amended restriction criteria
- Lamivudine tab 150 mg (Lamivudine Viatris) and oral liq 10 mg per ml – removal of restriction criteria
- Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride (Laceraine) gel 4% with 0.18% adrenaline and 0.5% tetracaine, 4 ml vial – price increase
- Lopinavir with ritonavir – removal of restriction criteria
 - Tab 100 mg with ritonavir 25 mg
 - Tab 200 mg with ritonavir 50 mg (Lopinavir/Ritonavir Mylan)
 - Oral liq 80 mg per ml with ritonavir 20 mg per ml
- Methotrexate (Methotrexate Ebewe) inj 100 mg per ml, 50 ml vial – price increase and addition of PSS
- Morphine hydrochloride (RA-Morph) oral liq 2 mg per ml and oral liq 5 mg per ml – price increase and addition of PSS

Summary of decisions – effective 1 November 2026 (continued)

- Naltrexone hydrochloride (Naltrexone Lupin) tab 50 mg – new listing and addition of PSS
- Naltrexone hydrochloride (Naltraccord) tab 50 mg – to be delisted from 1 April 2027
- Nevirapine (Viramune Suspension) oral suspension 10 mg per ml – delisted 1 November 2026
- Nevirapine tab 200 mg (Nevirapine Viatris) and oral suspension 10 mg per ml – amended restriction criteria
- Nivolumab (Opdivo) inj 10 mg per ml, 4 ml vial and inj 10 mg per ml, 10 ml vial – amended restriction criteria
- Non-Nucleoside Reverse Transcriptase Inhibitors – removal of restriction criteria
- Nucleoside Reverse Transcriptase Inhibitors – removal of restriction criteria
- Oral feed 1.5 kcal/ml (Fortijuice (Apple), Fortijuice (Orange) and Fortijuice (Strawberry)) liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle – amended brand names
- Pioglitazone (Rising) tab 15 mg and 30 mg – new listing
- Protease Inhibitors – removal of restriction criteria
- Raltegravir potassium granules for oral liq 100 mg – new listing
- Raltegravir potassium tab 400 mg (Isentress) and tab 600 mg (Isentress HD) and granules for oral liq 100 mg – removal of restriction criteria
- Riboflavin tab 100 mg and cap 100 mg – amended restriction criteria
- Ritonavir (Norvir) tab 100 mg – removal of restriction criteria
- Sildenafil (Sildenafil (Umedica)) tab 50 mg – new listing
- Stavudine cap 30 mg, cap 40 mg and powder for oral soln 1 mg per ml – removal of restriction criteria
- Strand Transfer Inhibitors – removal of restriction criteria
- Tamsulosin hydrochloride (Aurobindo Tamsulosin) cap 400 mcg – delisted 1 November 2026
- Teriparatide (Teriparatide Teva) inj 250 mcg per ml, 2.4 ml – amended brand name
- Venetoclax (Venclexta) tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg, tab 10 mg, tab 50 mg and tab 100 mg – amended restriction criteria
- Venlafaxine (Venlofex) cap 75 mg – new listing
- Zidovudine cap 100 mg and oral liq 10 mg per ml (Retrovir) and inj 10 mg per ml, 20 ml vial (Retrovir IV) – removal of restriction criteria
- Zidovudine with lamivudine (Lamivudine/Zidovudine Viatris) tab 300 mg with lamivudine 150 mg – removal of restriction criteria

Changes to General Rules

We have made amendments to Pharmaceutical Schedule Rules to give effect to the Paediatric Oncology Funding Policy from 1 November 2026.

The changes are provided below (only relevant parts of the criteria are shown).

Part 8 – Funding Exceptions

8.1 General Exceptions

- a Named Patient Pharmaceutical Assessment (NPPA): An Unlisted pharmaceutical or a Hospital Pharmaceutical outside of any relevant Restrictions may be Given in accordance with the NPPA Policy, or
- b Paediatric Oncology: Health NZ Hospitals may Give (and will be eligible to receive a Subsidy for) any pharmaceutical ~~for use within a paediatric oncology/haematology service for the treatment of cancer:~~ **in accordance with the Paediatric Oncology Funding Policy.**

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 November 2026

ALIMENTARY TRACT AND METABOLISM

6	HYDROCORTISONE ACETATE (new listing) Rectal foam 10%, CFC free (14 applications).....	57.09	15 g	Cortifoam
10	INSULIN ASPART WITH INSULIN ASPART PROTAMINE (delisting) Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen.....	52.15	5	NovoMix 30 FlexPen
	Note – NovoMix 30 FlexPen inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen to be delisted from 1 July 2027.			
11	PIOGLITAZONE (new listing) Tab 15 mg..... Tab 30 mg.....	6.15 7.25	90 90	Rising Rising
14	CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE (new listing) Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet			<i>e.g. Picosalax</i>
19	RIBOFLAVIN (amended restriction criteria – affected criteria shown only) → Tab 100 mg → Cap 100 mg Restricted Initiation Metabolic physician or neurologist <i>Re-assessment required after 6 months</i> Either: 1 The patient has a suspected inborn error of metabolism that may respond to riboflavin supplementation; or 2 The patient is scheduled for assessment of ureteric patency during cystoscopy.			
27	CALCITRIOL (PSS start date delayed) Cap 0.25 mcg – 5% DV Feb Mar-27 to 2028 Cap 0.5 mcg – 5% DV Feb Apr-27 to 2028	6.31 10.94	100 100	Calcitriol Devatis Calcitriol Devatis
27	CALCITRIOL (delisting delayed) Cap 0.25 mcg.....	7.89	100	Calcitriol XL Calcitriol-AFT
	Note – delisting delayed from 1 February 2027 to 1 March 2027.			
	Cap 0.5 mcg.....	13.68	100	Calcitriol XL Calcitriol-AFT
	Note – delisting delayed from 1 February 2027 to 1 April 2027.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

CARDIOVASCULAR SYSTEM

43	CAPTOPRIL (amended restriction criteria) → Oral liq 5 mg per ml – 5% DV Feb-27 to 2029	98.90	100 ml	DP-Captopril
	Restricted Initiation Any of the following: 1 For use in children under 12 years of age; or 2 For use in tube-fed patients; or 3 For management of rebound transient hypertension following cardiac surgery; or 4 For treatment of acute autonomic dysreflexia in any person with spinal cord injury where glyceryl trinitrate is not tolerated, not clinically suitable or cannot be self-administered.			
45	FLECAINIDE ACETATE (delisted) Inj 10 mg per ml, 15 ml ampoule	102.79 108.16	5	Almarytm Tambocor German
	Note – Almarytm and Tambocor German inj 10 mg per ml, 15 ml ampoule delisted 1 November 2026.			
60	SILDENAFIL (new listing) → Tab 50 mg.....	1.45	4	Sildenafil (Umedica)

GENITO-URINARY SYSTEM

75	TAMSULOSIN HYDROCHLORIDE (delisted) → Cap 400 mcg.....	28.56	100	Aurobindo Tamsulosin
	Note – Aurobindo Tamsulosin cap 400 mcg delisted 1 November 2026.			

INFECTIONS

90	CEFTOLOZANE WITH TAZOBACTAM (new listing) → Inj 1,000 mg with tazobactam 500 mg, 20 ml vial	2,500.00	10	Zerbaxa
	Restricted Initiation – Multi-drug resistant organisms Clinical microbiologist or infectious disease specialist Either: 1 For the treatment of infection with a microorganism proven to be resistant to other funded antibiotics, based on microbiology reporting; or 2 For the treatment of infection with an organism reasonably expected to be resistant to other funded antibiotics but susceptible to ceftolozane with tazobactam.			
97	FLUCONAZOLE (new listing) → Cap 200 mg	8.90	28	APO Fluconazole

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
Changes to Section H Part II – effective 1 November 2026 (continued)				
100	BEDAQUILINE (amended restriction criteria – new criteria shown only) → Tab 100 mg.....	3,084.51	24	Sirturo
	Restricted Initiation – Non-tuberculosis mycobacteria Re-assessment required after 12 months Both: 1 The person has non-tuberculosis mycobacteria (NTM) infection; and 2 Ministry of Health’s Tuberculosis Clinical Network has reviewed the individual case and recommends bedaquiline as part of the treatment regimen. Continuation — Non-tuberculosis mycobacteria Re-assessment required after 12 months Both: 1 The person has non-tuberculosis mycobacteria (NTM) infection; and 2 Ministry of Health’s Tuberculosis Clinical Network has reviewed the individual case and continues to recommend bedaquiline as part of the treatment regimen.			
103	Antiretrovirals (addition of note) Note: HIV treatment with antiretroviral medicines should only be initiated under the guidance of a clinician experienced in the management of HIV. Practitioners should refer to local health pathways and guidelines.			
103	Non-Nucleoside Reverse Transcriptase Inhibitors (removal of restriction criteria) Restricted Initiation—Confirmed HIV Patient has confirmed HIV infection. Initiation—Prevention of maternal transmission Either: 1—Prevention of maternal foetal transmission; or 2—Treatment of the newborn for up to eight weeks. Initiation—Post-exposure prophylaxis following exposure to HIV Both: 1—Treatment course to be initiated within 72 hours post exposure; and 2—Any of the following: 2.1—Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or 2.2—Patient has shared intravenous injecting equipment with a known HIV positive person; or 2.3—Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or 2.4—Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown. Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/). Initiation—Percutaneous exposure Patient has percutaneous exposure to blood known to be HIV positive			
104	EFAVIRENZ (removal of restriction criteria) → Oral liq 30 mg per ml			
104	ETRAVIRINE (removal of restriction criteria) → Tab 200 mg.....	770.00	60	Intelligence

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

104	NEVIRAPINE (delisting brand only) → Oral suspension 10 mg per ml.....	203.55	240 ml	Viramune Suspension
	Note – Viramune Suspension oral suspension 10 mg per ml delisted 1 November 2026.			
104	NEVIRAPINE (removal of restriction criteria) → Tab 200 mg – 5% DV Feb-25 to 2027	198.25	60	Nevirapine Viatris
	→ Oral suspension 10 mg per ml			
104	Nucleoside Reverse Transcriptase Inhibitors (removal of restriction criteria)			
	Restricted			
	Initiation—Confirmed HIV			
	Patient has confirmed HIV infection:			
	Initiation—Prevention of maternal transmission			
	Either:			
	1—Prevention of maternal foetal transmission; or			
	2—Treatment of the newborn for up to eight weeks.			
	Initiation—Post-exposure prophylaxis following exposure to HIV			
	Both:			
	1—Treatment course to be initiated within 72 hours post exposure; and			
	2—Any of the following:			
	2.1—Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or			
	2.2—Patient has shared intravenous injecting equipment with a known HIV positive person; or			
	2.3—Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or			
	2.4—Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown.			
	Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/).			
	Initiation—Percutaneous exposure			
	Patient has percutaneous exposure to blood known to be HIV positive.			
104	ABACAVIR SULPHATE (removal of restriction criteria) → Tab 300 mg.....	180.00	60	Ziagen
	→ Oral liq 20 mg per ml			
104	ABACAVIR SULPHATE WITH LAMIVUDINE (removal of restriction criteria) → Tab 600 mg with lamivudine 300 mg — 5% DV Feb-26 to 2028	35.00	30	Abacavir/lamivudine Viatris
105	EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL (removal of restriction criteria)			
	→ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a maleate).....			
		106.88	30	Viatris
	→ Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil 245 mg (300 mg as a fumarate)			
		106.88	30	TEEVIR TEEVIR (India) Tenofovir Efavirenz Emtricitabine (Mylan)

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

105	EMTRICITABINE (removal of restriction criteria) → Cap 200 mg.....	307.20	30	Emtriva
105	LAMIVUDINE (removal of restriction criteria) → Tab 150 mg – 5% DV Feb-27 to 2029 → Oral liq 10 mg per ml	150.00	60	Lamivudine Viatris
105	STAVUDINE (removal of restriction criteria) → Cap 30 mg → Cap 40 mg → Powder for oral soln 1 mg per ml			
105	ZIDOVUDINE (removal of restriction criteria) → Cap 100 mg..... → Oral liq 10 mg per ml → Inj 10 mg per ml, 20 ml vial.....	152.25 30.45 750.00	100 200 ml 5	Retrovir Retrovir Retrovir IV
105	ZIDOVUDINE WITH LAMIVUDINE (removal of restriction criteria) → Tab 300 mg with lamivudine 150 mg	92.40	60	Lamivudine/Zidovudine Viatris
105	Protease Inhibitors (removal of restriction criteria) Restricted Initiation—Confirmed HIV Patient has confirmed HIV infection: Initiation—Prevention of maternal transmission Either: 1—Prevention of maternal foetal transmission; or 2—Treatment of the newborn for up to eight weeks. Initiation—Post-exposure prophylaxis following exposure to HIV Both: 1—Treatment course to be initiated within 72 hours post exposure; and 2—Any of the following: 2.1 Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person; or 2.3 Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or 2.4 Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown. Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/). Initiation—Percutaneous exposure Patient has percutaneous exposure to blood known to be HIV positive.			
106	ATAZANAVIR SULPHATE (removal of restriction criteria) → Cap 150 mg – 5% DV Feb-26 to 2028 → Cap 200 mg – 5% DV Feb-26 to 2028	102.50 152.30	60 60	Atazanavir Viatris Atazanavir Viatris

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

106	DARUNAVIR (removal of restriction criteria) → Tab 400 mg – 5% DV Dec-26 to 2029 115.00 → Tab 600 mg – 5% DV Dec-26 to 2029 130.00	60 60		Darunavir Viatris Darunavir Viatris
106	INDINAVIR (removal of restriction criteria) → Cap 200 mg → Cap 400 mg			
106	LOPINAVIR WITH RITONAVIR (removal of restriction criteria) → Tab 100 mg with ritonavir 25 mg → Tab 200 mg with ritonavir 50 mg – 5% DV Feb-25 to 2027 .. 875.00 → Oral liq 80 mg per ml with ritonavir 20 mg per ml	120		Lopinavir/Ritonavir Mylan
106	RITONAVIR (removal of restriction criteria) → Tab 100 mg..... 43.31	30		Norvir
106	Strand Transfer Inhibitors (removal of restriction criteria) Restricted Initiation—Confirmed HIV Patient has confirmed HIV infection. Initiation—Prevention of maternal transmission Either: 1—Prevention of maternal foetal transmission; or 2—Treatment of the newborn for up to eight weeks. Initiation—Post-exposure prophylaxis following exposure to HIV Both: 1—Treatment course to be initiated within 72 hours post exposure; and 2—Any of the following: 2.1—Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml; or 2.2—Patient has shared intravenous injecting equipment with a known HIV positive person; or 2.3—Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required; or 2.4—Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown. Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (https://www.ashm.org.au/hiv/hiv-management/pep/). Initiation—Percutaneous exposure Patient has percutaneous exposure to blood known to be HIV positive.			
106	DOLUTEGRAVIR (new listing) Tab dispersible 5 mg			
106	DOLUTEGRAVIR (removal of restriction criteria) → Tab 50 mg 1,090.00	30		Tivicay
107	DOLUTEGRAVIR WITH LAMIVUDINE (removal of restriction criteria) → Tab 50 mg with lamivudine 300 mg 1,090.00	30		Dovato

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

107	RALTEGRAVIR POTASSIUM (new listing) Grans for oral liq 100 mg			
107	RALTEGRAVIR POTASSIUM (removal of restriction criteria) → Tab 400 mg.....	1,090.00	60	Isentress
	→ Tab 600 mg.....	1,090.00	60	Isentress HD
109	EMTRICITABINE WITH TENOFOVIR DISOPROXIL (removal of restriction criteria) → Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a maleate) – 5% DV Dec-25 to 2028	13.45	30	Tenofovir Disoproxil Emtricitabine Viatr
	→ Tab 200 mg with tenofovir disoproxil 245 mg (300 mg as a fumarate).....	13.45	30	Tenofovir Disoproxil Emtricitabine Mylan

Restricted

Initiation—Confirmed HIV

Patient has confirmed HIV infection:

Initiation—Prevention of maternal transmission

Either:

- 1—Prevention of maternal foetal transmission; or
- 2—Treatment of the newborn for up to eight weeks.

Initiation—Post-exposure prophylaxis following non-occupational exposure to HIV

Both:

- 1—Treatment course to be initiated within 72 hours post exposure; and
- 2—Any of the following:
 - 2.1—Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2—Patient has shared intravenous injecting equipment with a known HIV positive person; or
 - 2.3—Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required.

Initiation—Percutaneous exposure

Patient has percutaneous exposure to blood known to be HIV positive.

Initiation—Pre-exposure prophylaxis

Re-assessment required after 24 months

Both:

- 1—Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2—The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (<https://ashm.org.au/HIV/PrEP/>)

Continuation—Pre-exposure prophylaxis

Re-assessment required after 24 months

Both:

- 1—Patient has tested HIV negative, does not have signs or symptoms of acute HIV infection and has been assessed for HIV seroconversion; and
- 2—The Practitioner considers the patient is at elevated risk of HIV exposure and use of PrEP is clinically appropriate.

Note: Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines (<https://ashm.org.au/HIV/PrEP/>)

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

MUSCULOSKELETAL SYSTEM

115	TERIPARATIDE (amended brand name) → Inj 250 mcg per ml, 2.4 ml.....	200.27	1	Teriparatide Teva S29
118	IBUPROFEN (new listing and addition of PSS) Tab 200 mg - 20 tablet pack – 5% DV Jun-27 to 2029	0.90	20	Ibuprofen-AFT

NERVOUS SYSTEM

124	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE (↑ price) Gel 4% with 0.18% adrenaline and 0.5% tetracaine, 4 ml vial.....	107.00	5	Laceraine
124	ASPIRIN (↑ price and addition of PSS) Tab dispersible 300 mg – 5% DV Apr-27 to 2029	6.20	100	Ethics Aspirin
126	MORPHINE HYDROCHLORIDE (↑ price and addition of PSS) Oral liq 2 mg per ml – 5% DV Apr-27 to 2029	27.55	200 ml	RA-Morph
	Oral liq 5 mg per ml – 5% DV Apr-27 to 2029	33.00	200 ml	RA-Morph
128	VENLAFAXINE (new listing) Cap 75 mg	3.44	28	Venlofex
148	NALTREXONE HYDROCHLORIDE (brand change and addition of PSS) → Tab 50 mg – 5% DV Apr-27 to 2029	69.03	30	Naltrexone Lupin
	Note – Naltraccord tab 50 mg to be delisted from 1 April 2027.			

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

153	METHOTREXATE (↑ price and addition of PSS) Inj 100 mg per ml, 50 ml vial – 5% DV Apr-27 to 2029	159.77	1	Methotrexate Ebewe
154	IBRUTINIB (amended restriction criteria – affected criteria shown only) → Tab 140 mg.....	3,217.00	30	Imbruvica
	→ Tab 420 mg.....	9,652.00	30	Imbruvica
	Restricted			
	Initiation – previously untreated chronic lymphocytic leukaemia in combination with venetoclax			
	Either:			
	1 Individual is currently on treatment with ibrutinib and/or venetoclax and met all of the following criteria prior to commencing treatment; or			
	2 Both:			
	1-1 1 Individual has previously untreated CLL; and			
	2-2 2 Ibrutinib is to be administered at a maximum dose of 420 mg daily for 3 (28 day) cycles as monotherapy, followed by a maximum of 12 (28 day) cycles in combination with venetoclax.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

- 159 VENETOCLAX (amended restriction criteria – affected criteria shown only)
- | | | | |
|---|----------|-----|-----------|
| → Tab 14 × 10 mg, 7 × 50 mg, 21 × 100 mg..... | 1,771.86 | 42 | Venclexta |
| → Tab 10 mg..... | 13.68 | 2 | Venclexta |
| → Tab 50 mg..... | 239.44 | 7 | Venclexta |
| → Tab 100 mg..... | 8,209.41 | 120 | Venclexta |
- Restricted
Initiation – previously untreated chronic lymphocytic leukaemia in combination with ibrutinib
~~Either:~~
- ~~1 Individual is currently on treatment with venetoclax and/or ibrutinib and met all of the following criteria prior to commencing treatment; or~~
 - 2 All of the following:
 - 2-1 1 Individual has previously untreated chronic lymphocytic leukaemia; and
 - 2-2 2 Venetoclax is to be administered in combination with ibrutinib; and
 - 2-3 3 Venetoclax is to be used to a maximum dose of 400 mg and for a total of 12 (28 day) cycles.
- 165 IMATINIB MESILATE (↓ price and addition of PSS)
- | | | | |
|--|-------|----|---------------------|
| Cap 100 mg – 5% DV Apr-27 to 2029 | 41.00 | 60 | Imatinib-Rex |
| Cap 400 mg – 5% DV Apr-27 to 2029 | 63.00 | 30 | Imatinib-Rex |
- 183 ADALIMUMAB (AMGEVITA) (amended restriction criteria – affected criteria shown only)
- | | | | |
|--|--------|---|----------|
| → Inj 20 mg per 0.4 ml prefilled syringe | 190.00 | 1 | Amgevita |
| → Inj 40 mg per 0.8 ml prefilled pen..... | 375.00 | 2 | Amgevita |
| → Inj 40 mg per 0.8 ml prefilled syringe | 375.00 | 2 | Amgevita |
- Restricted
Continuation – Hidradenitis suppurativa
~~Any relevant practitioner~~
Re-assessment required after 2 years
~~Both:~~
- 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; ~~and or~~
 - 2 The patient has a DLQI improvement of 4 or more from baseline.
- 192 ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND) (amended restriction criteria – affected criteria shown only)
- | | | | |
|--|--------|---|-----------|
| → Inj 20 mg per 0.2 ml prefilled syringe | 595.50 | 2 | Humira |
| → Inj 40 mg per 0.4 ml prefilled syringe | 595.50 | 2 | Humira |
| → Inj 40 mg per 0.4 ml prefilled pen..... | 595.50 | 2 | HumiraPen |
- Restricted
Continuation – Hidradenitis suppurativa
Dermatologist or Practitioner on the recommendation of a dermatologist
Re-assessment required after 6 months
Both:
- 1 **Either** All of the following:
 - 1.1 1 The patient has a reduction in active lesions (e.g. inflammatory nodules, abscesses, draining fistulae) of 25% or more from baseline; ~~and or~~
 - 1.2 2 The patient has a **DLQI Dermatology Quality of Life Index** improvement of 4 or more from baseline; and
 - 2 3 Adalimumab is to be administered at doses no greater than 40mg every 7 days. Fortnightly dosing has been considered.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

245	IPILIMUMAB (amended restriction criteria – affected criteria shown only)		
	→ Inj 5 mg per ml, 10 ml vial	5,000.00	1 Yervoy
	→ Inj 5 mg per ml, 40 ml vial	20,000.00	1 Yervoy
	Restricted		
	Initiation – stage III or IV resectable melanoma		
	Either:		
	1 The individual is currently on treatment with ipilimumab for neoadjuvant treatment of resectable stage IIIB, IIIC, IIID or IV melanoma and met all remaining criteria prior to commencing treatment; or		
	2 All of the following:		
	1 2-1 The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note); and		
	2 2-2 The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma; and		
	3 2-3 The individual has ECOG performance score 0-2; and		
	4 2-4 Treatment must be prior to complete surgical resection; and		
	5 2-5 Neoadjuvant ipilimumab must be administered in combination with nivolumab; and		
	6 2-6 Ipilimumab to be administered for maximum of two cycles prior to surgical resection.		
	Note:		
	a) Stage IIIB, IIIC, IIID or IV melanoma defined as per American Joint Committee on Cancer (AJCC) 8th Edition.		
	b) Disease must be completely resectable and amenable to curative intent surgery, including stage IV disease.		
246	NIVOLUMAB (amended restriction criteria – affected criteria shown only)		
	→ Inj 10 mg per ml, 4 ml vial	1,051.98	1 Opdivo
	→ Inj 10 mg per ml, 10 ml vial	2,629.96	1 Opdivo
	Restricted		
	Initiation – stage III or IV resectable melanoma		
	<i>Re-assessment required after 4 months</i>		
	Either:		
	1 The individual is currently on treatment with nivolumab for neoadjuvant treatment of resectable stage IIIB, IIIC, IIID or IV melanoma and met all remaining criteria prior to commencing treatment; or		
	2 All of the following:		
	1 2-1 The individual has resectable stage IIIB, IIIC, IIID or IV melanoma (excluding uveal) (see note); and		
	2 2-2 The individual has not received prior funded systemic treatment in the perioperative setting for their stage IIIB, IIIC, IIID or IV melanoma; and		
	3 2-3 The individual has ECOG performance score 0-2; and		
	4 2-4 Treatment must be initiated prior to complete surgical resection; and		
	5 2-5 Neoadjuvant nivolumab must be administered in combination with ipilimumab; and		
	6 2-6 Nivolumab to be administered for maximum of two cycles prior to surgical resection.		

RESPIRATORY SYSTEM AND ALLERGIES

264	CETIRIZINE HYDROCHLORIDE (brand change and addition of PSS)		
	Oral liq 1 mg per ml – 5% DV Apr-27 to 2029	2.64	200 ml Noumed Cetirizine Hayfever & Allergy Relief
	Note – Histaclear oral liq 1 mg per ml to be delisted from 1 April 2027.		

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2026 (continued)

SPECIAL FOODS

308	ORAL FEED 1.5 KCAL/ML (amended brand name) → Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle	3.30	200 ml	Forti juice (Apple) (Apple) Forti juice (Orange) (Orange) Forti juice (Strawberry) (Strawberry)
				Forti juice Forti juice Forti juice

VACCINES

316	HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV] (amended restriction criteria – affected criteria shown only) → Inj 270 mcg in 0.5 ml syringe – 5% DV Dec-24 to 2027	0.00	10	Gardasil 9
	Restricted Initiation – Other conditions Either: 1 Up to 3 doses for people aged 15 to 26 years inclusive; or 2 Both: 2.1 People aged 9 to 26 years inclusive; and 2.2 Any of the following: 2.2.1 Up to 3 doses for confirmed HIV infection; or 2.2.2 Up to 3 doses for people with a transplant (including stem cell); or 2.2.3 Up to 4 doses for Post chemotherapy Up to 3 doses for people with severe immunosuppressive conditions or receiving severely immunosuppressive therapy; or 2.2.4 Up to 4 doses for people post chemotherapy			

Index

Pharmaceuticals and brands

A

Abacavir/lamivudine Viatris.....	10
ABACAVIR SULPHATE	10
ABACAVIR SULPHATE WITH LAMIVUDINE	10
ADALIMUMAB (AMGEVITA)	15
ADALIMUMAB (HUMIRA - ALTERNATIVE BRAND).....	15
Almarytm	8
Amgevita	15
APO Fluconazole	8
ASPIRIN.....	14
ATAZANAVIR SULPHATE	11
Atazanavir Viatris.....	11
Aurobindo Tamsulosin	8

B

BEDAQUILINE	9
-------------------	---

C

CALCITRIOL.....	7
Calcitriol-AFT	7
Calcitriol Devatis	7
Calcitriol XL.....	7
CAPTOPRIL	8
CEFTOLOZANE WITH TAZOBACTAM.....	8
CETIRIZINE HYDROCHLORIDE.....	16
CITRIC ACID WITH MAGNESIUM OXIDE AND SODIUM PICOSULFATE.....	7
Cortifoam.....	7

D

DARUNAVIR.....	12
Darunavir Viatris.....	12
DOLUTEGRAVIR.....	12
DOLUTEGRAVIR WITH LAMIVUDINE	12
Dovato	12
DP-Captopril	8

E

EFAVIRENZ	9
EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPROXIL	10
EMTRICITABINE.....	11
EMTRICITABINE WITH TENOFOVIR DISOPROXIL	13
Emtriva	11
Ethics Aspirin	14
ETRAVIRINE.....	9

F

FLECAINIDE ACETATE.....	8
FLUCONAZOLE	8
Fortijuice (Apple).....	17
Fortijuice (Orange)	17
Fortijuice (Strawberry).....	17
Fortijuice (Apple).....	17
Fortijuice (Orange)	17
Fortijuice (Strawberry).....	17

G

Gardasil 9	17
------------------	----

H

HPV	17
HUMAN PAPILLOMAVIRUS (6, 11, 16, 18, 31, 33, 45, 52 AND 58) VACCINE [HPV]	17
Humira.....	15
HumiraPen.....	15
HYDROCORTISONE ACETATE	7

I

IBRUTINIB.....	14
IBUPROFEN	14
Ibuprofen-AFT	14
IMATINIB MESILATE	15
Imatinib-Rex.....	15
Imbruvica.....	14
INDINAVIR	12
INSULIN ASPART WITH INSULIN ASPART PROTAMINE.....	7
Intelence.....	9
IPIILIMUMAB	16
Isentress.....	13
Isentress HD	13

L

Laceraïne	14
LAMIVUDINE.....	11
Lamivudine Viatris.....	11
Lamivudine/Zidovudine Viatris	11
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE WITH ADRENALINE AND TETRACAINE HYDROCHLORIDE.....	14
LIGNOCAINE	14
Lopinavir/Ritonavir Mylan.....	12
LOPINAVIR WITH RITONAVIR.....	12

M

METHOTREXATE.....	14
Methotrexate Ebewe.....	14
MORPHINE HYDROCHLORIDE.....	14

N

NALTREXONE HYDROCHLORIDE.....	14
Naltrexone Lupin	14
NEVIRAPINE	10
Nevirapine Viatris	10
NIVOLUMAB	16
Norvir	12
Noumed Cetirizine Hayfever & Allergy Relief	16
NovoMix 30 FlexPen.....	7

O

Opdivo	16
ORAL FEED 1.5 KCAL/ML	17

P

Picosalax	7
PIOGLITAZONE.....	7

R

RALTEGRAVIR POTASSIUM.....	13
RA-Morph	14
Retrovir.....	11

Index

Pharmaceuticals and brands

Retrovir IV.....	11
RIBOFLAVIN.....	7
Rising.....	7
RITONAVIR.....	12

S

SILDENAFIL.....	8
Sildenafil (Umedica).....	8
Sirturo.....	9
STAVUDINE.....	11

T

Tambocor German.....	8
TAMSULOSIN HYDROCHLORIDE.....	8
TEEVIR.....	10
TEEVIR (India).....	10
Tenofovir Disoproxil Emtricitabine Mylan.....	13
Tenofovir Disoproxil Emtricitabine Viatr.....	13
Tenofovir Efavirenz Emtricitabine (Mylan).....	10

TERIPARATIDE.....	14
Teriparatide Teva.....	14
Teriparatide Teva S29.....	14
Tivicay.....	12

V

Venclexta.....	15
VENETOCLAX.....	15
VENLAFAXINE.....	14
Venlofex.....	14
Viramune Suspension.....	10

Y

Yervoy.....	16
-------------	----

Z

Zerbaxa.....	8
Ziagen.....	10
ZIDOVUDINE.....	11
ZIDOVUDINE WITH LAMIVUDINE.....	11

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

